^
    11d
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Ojjaara (momelotinib)
    2ms
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Dec 2027 --> Mar 2028
    Trial primary completion date
    |
    azacitidine • Ojjaara (momelotinib)
    2ms
    A Phase 2 Study of Gecacitinib in Patients with Chronic Neutrophilic Leukemia (CNL) and myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN-SFCB1-T) (ChiCTR2500113793)
    P2, N=28, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.; Institute of Hematolog
    New P2 trial
    |
    SF3B1 (Splicing Factor 3b Subunit 1)
    2ms
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov)
    P=N/A, N=153, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Valcyte (valganciclovir)
    5ms
    The Dual Role of Interferon Signaling in Myeloproliferative Neoplasms: Pathogenesis and Targeted Therapeutics. (PubMed, Cancers (Basel))
    Understanding the dichotomous effects of IFNs in MPNs not only clarifies their role in disease biology but also informs their optimal use in clinical practice. This duality highlights the need for personalized approaches to IFN-based therapies.
    Review • Journal
    |
    ABL1 (ABL proto-oncogene 1) • IFNA1 (Interferon Alpha 1)
    5ms
    Colony-Stimulating Factor 3 Receptor Mutations and Variants in Hematological Malignancies. (PubMed, Cancers (Basel))
    This review provides an overview of CSF3R, the various pathogenic CSF3R mutations/variants and their biological effects. It also details the diseases to which they contribute, notably including chronic neutrophilic leukemia (CNL) and other myeloproliferative neoplasms (MPNs), myelodysplastic neoplasms (MDS), combined MDS/MPN disorders such as atypical chronic myeloid leukemia (aCML) and chronic myelomonocytic leukemia (CMML), as well as acute myeloid leukemia (AML) and lymphoid malignancies.
    Review • Journal
    |
    CSF3R (Colony Stimulating Factor 3 Receptor)
    8ms
    Research progress on the mechanisms of CSF3R mutations in leukemogenesis and treatment strategies. (PubMed, Cancer Cell Int)
    In-depth research on the CSF3R genes and their related mechanisms will help further reveal the mechanisms of leukemia development and provide potential targets for treatment. Therefore, this paper mainly focuses on the roles of colony-stimulating factor 3 (CSF3R) in hematopoiesis and the occurrence of leukemia, with particular attention to the roles of CSF3R in the JAK-STAT, PI3K-AKT, and MAPK-ERK signaling pathways.
    Review • Journal
    |
    CSF3R (Colony Stimulating Factor 3 Receptor)
    8ms
    Expanding the Spectrum of CSF3R-Mutated Myeloid Neoplasm Beyond Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia: A Comprehensive Analysis of 13 Cases. (PubMed, J Clin Med)
    Survival analysis revealed distinct patterns across the three diagnostic groups, with MDS/MPN having the poorest prognosis. This study expands the recognized spectrum of CSF3R-related myeloid neoplasms and highlights the clinical and molecular heterogeneity associated with these mutations, emphasizing the need for comprehensive molecular profiling and the potential for targeted therapies.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • CSF3R (Colony Stimulating Factor 3 Receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • JAK3 (Janus Kinase 3) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    9ms
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P1 trial
    |
    azacitidine • decitabine • Ojjaara (momelotinib)
    9ms
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov)
    P=N/A, N=153, Active, not recruiting, City of Hope Medical Center | Completed --> Active, not recruiting | Trial completion date: Dec 2013 --> Dec 2025
    Enrollment closed • Trial completion date
    |
    Valcyte (valganciclovir)
    9ms
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov)
    P=N/A, N=153, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    Valcyte (valganciclovir)
    9ms
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov)
    P=N/A, N=153, Active, not recruiting, City of Hope Medical Center | Completed --> Active, not recruiting | Trial completion date: Dec 2013 --> Dec 2025
    Enrollment closed • Trial completion date
    |
    Valcyte (valganciclovir)